Skip to main content
Skip to main content
COSM logo

COSM (COSM)

$0.27 +$0.04 (+15.48%) |Avoid · 20
Bottom line: SELL — our Council read (20/100) and AI Score (20/100) broadly agree.
MCap: $17.00M| P/E Ratio: 5.2| Vol: 18.91M| Target: $4.50 (+1543.5%)|
Data from FMP · Methodology

For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

COSM (COSM) trades at $0.27 with AI Score 20/100 (Grade F). Cosmos Health Inc. is a vertically integrated pharmaceutical company focused on branded and generic pharmaceuticals, nutraceuticals, and OTC medications. Market cap: $17.00M, Sector: Healthcare.

Price live · AI analysis from May 4, 2026
Cosmos Health Inc. is a vertically integrated pharmaceutical company focused on branded and generic pharmaceuticals, nutraceuticals, and OTC medications. The company operates through distribution channels and an e-commerce marketplace, primarily serving wholesale pharmaceutical distributors and independent retail pharmacies.

COSM stock analysis for 2026: Analysts have set a consensus price target of $4.50 for COSM, suggesting 1543.5% upside from the current price of $0.27. The AI MoonshotScore is 20/100, indicating a strong bearish outlook. Key factors: analyst coverage, AI-driven quantitative scoring.

Council Score · Weighted Average of 3 Disciplines
SELL 20/100 · F

COSM: 1/1 perspectives are bearish.

How is this calculated? →
Council Score · 8 perspectives · See tabs for details →

COSM (COSM) Healthcare & Pipeline Overview

CEOGrigorios Siokas
Employees149
HeadquartersChicago, IL, US
IPO Year2010

Cosmos Health Inc. is a vertically integrated pharmaceutical company that operates in the specialty and generic drug market, offering a range of products from pharmaceuticals to medical devices. With a small market capitalization and negative profitability, Cosmos Health aims to expand its proprietary product line and leverage its European distribution network.

Data Provenance | Financial Data Quantitative Analysis NASDAQ Analysis: May 4, 2026

What Is the Investment Thesis for COSM?

The investment thesis for Cosmos Health Inc. centers on its potential to leverage its vertically integrated structure and European distribution network to expand its market presence. Key to this thesis is the successful commercialization of its proprietary product line, which could drive revenue growth. However, the company's current financial standing, characterized by a small market capitalization of approximately $13 million and a negative profit margin of -29.3%, presents significant risks. Investors should monitor the company's ability to improve its gross margin, currently at 12.1%, and manage its high beta of 4.46, reflecting significant market volatility. The success of Cosmos Health hinges on its ability to execute its growth strategy and achieve profitability in a competitive market.

Based on FMP financials and quantitative analysis

COSM Key Highlights

  • Market Cap of $17.00M indicates a small capitalization company with potential for high growth but also higher risk.
  • Profit Margin of -29.3% reflects current challenges in achieving profitability, requiring significant operational improvements.
  • Gross Margin of 12.1% is relatively low, suggesting potential issues with cost of goods sold or pricing strategy.
  • Beta of 4.46 indicates high volatility compared to the market, making it a riskier investment.
  • Vertically integrated operations provide control over the supply chain, potentially leading to cost efficiencies and better quality control.

Who Are COSM's Competitors?

COSM is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

Company Price Change Market Cap AI Score
TEVA Teva Pharmaceutical Industries Limited $35.29 +1.88% $41.09B 44
ALVO Alvotech $3.51 -2.77% $1.19B 69
AERI Aerie Pharmaceuticals, Inc. $15.25 +0.00% 68
KIN Kindred Biosciences, Inc. $9.25 +0.11% 68
CNVCF BioHarvest Sciences Inc. $6.30 +0.00% $109.16M 66
ALIM Alimera Sciences, Inc. $5.54 -0.18% $301.29M 60
EGRX Eagle Pharmaceuticals, Inc. $0.67 +0.00% $8.82M 60
ADMP Adamis Pharmaceuticals Corporation $0.78 +0.85% $7.25M 61

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are COSM's Key Strengths?

  • Vertically integrated operations
  • Distribution network in Europe
  • Proprietary line of branded products
  • E-commerce marketplace

What Are COSM's Weaknesses?

  • Small market capitalization
  • Negative profit margin
  • Low gross margin
  • High beta indicating high volatility

What Could Drive COSM Stock Higher?

  • Launch of new proprietary pharmaceutical products aimed at specific therapeutic areas, expected in Q3 2026.
  • Expansion of the e-commerce platform to increase direct-to-consumer sales and improve customer engagement.
  • Strategic partnerships with European distributors to enhance market penetration and expand geographic reach.

What Are the Key Risks for COSM?

  • Financial-distress signal — its Altman Z-Score of -2.63 sits in the distress zone (elevated bankruptcy risk).
  • Negative return on equity (-96.5%) — the business is not currently generating profit on shareholder capital.
  • Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
  • Intense competition from larger pharmaceutical companies with greater resources and market share.
  • Regulatory hurdles and compliance requirements that could delay product approvals and increase operational costs.
  • Economic downturns affecting consumer spending on healthcare products and nutraceuticals.
  • Fluctuations in currency exchange rates impacting revenue and profitability in European markets.

What Are the Growth Opportunities for COSM?

  • Expansion of Proprietary Product Line: Cosmos Health has the opportunity to grow by expanding its line of branded and generic pharmaceuticals, nutraceuticals, and over-the-counter medications. The global nutraceuticals market, for instance, is projected to reach $500 billion by 2025, presenting a significant opportunity. Successfully developing and marketing new products in this space could drive revenue growth and improve profitability for Cosmos Health. This expansion hinges on effective R&D and marketing strategies.
  • Leveraging European Distribution Network: With distribution centers in Greece and the United Kingdom, Cosmos Health can leverage its existing infrastructure to expand its market reach across Europe. The European pharmaceutical market is one of the largest in the world, offering substantial growth potential. By strengthening relationships with wholesale pharmaceutical distributors and independent retail pharmacies, Cosmos Health can increase its sales volume and market share. This requires strategic partnerships and efficient logistics management.
  • E-commerce Marketplace Growth: Cosmos Health's e-commerce marketplace provides a direct-to-consumer channel that can drive revenue growth and improve brand visibility. The global e-commerce market is rapidly expanding, with healthcare products representing a growing segment. By enhancing its online platform, improving customer experience, and implementing targeted marketing campaigns, Cosmos Health can attract more customers and increase online sales. This strategy requires investments in technology and digital marketing.
  • Strategic Acquisitions: Cosmos Health can pursue strategic acquisitions to expand its product portfolio, geographic reach, and market share. Acquiring complementary businesses or product lines can provide synergies and accelerate growth. For example, acquiring a company with a strong presence in a specific therapeutic area or geographic market could significantly enhance Cosmos Health's competitive position. However, successful acquisitions require careful due diligence and integration planning.
  • Development of Medical Devices: Cosmos Health's involvement in medical devices presents a growth opportunity, particularly in specialized segments. The global medical device market is characterized by innovation and technological advancements. By focusing on developing and commercializing innovative medical devices, Cosmos Health can tap into a high-growth market segment. This requires investments in R&D, regulatory approvals, and strategic partnerships with healthcare providers.

What Opportunities Does COSM Have?

  • Expansion of proprietary product line
  • Leveraging European distribution network
  • Growth of e-commerce marketplace
  • Strategic acquisitions

What Threats Does COSM Face?

  • Intense competition in the pharmaceutical industry
  • Regulatory scrutiny and compliance requirements
  • Economic downturns affecting consumer spending
  • Fluctuations in currency exchange rates

What Are COSM's Competitive Advantages?

  • Vertically integrated operations provide control over the supply chain.
  • Distribution centers in Europe offer a strategic advantage in the European market.
  • Proprietary line of branded products differentiates it from generic competitors.
  • E-commerce marketplace provides a direct-to-consumer sales channel.

What Does COSM Do?

Cosmos Health Inc., established in 2009 and headquartered in Chicago, Illinois, operates as a vertically integrated pharmaceutical company. The company focuses on identifying, acquiring, developing, and commercializing a diverse range of healthcare products. These include branded and generic pharmaceuticals, nutraceuticals, over-the-counter medications, health care and baby products, and medical devices. Cosmos Health distributes these products through its established distribution channels and an e-commerce marketplace, catering to wholesale pharmaceutical distributors and independent retail pharmacies. With distribution centers strategically located in Greece and the United Kingdom, Cosmos Health maintains a warehousing facility to support its operations. The company's vertically integrated model allows it to manage various aspects of the supply chain, from product development to distribution, aiming to enhance efficiency and control. Cosmos Health's strategy involves expanding its proprietary product line and leveraging its European distribution network to drive growth and improve profitability in the competitive pharmaceutical market.

What Products and Services Does COSM Offer?

  • Develop and commercialize branded and generic pharmaceuticals.
  • Offer a range of nutraceutical products.
  • Provide over-the-counter medications for various health conditions.
  • Distribute health care and baby products.
  • Offer medical devices through various channels.
  • Operate an e-commerce marketplace for direct-to-consumer sales.
  • Serve wholesale pharmaceutical distributors and independent retail pharmacies.

How Does COSM Make Money?

  • Develop, acquire, and commercialize healthcare products.
  • Distribute products through wholesale and retail channels.
  • Operate an e-commerce marketplace for direct sales.
  • Generate revenue from the sale of pharmaceuticals, nutraceuticals, and medical devices.

What Industry Does COSM Operate In?

Cosmos Health Inc. operates within the specialty and generic drug manufacturing industry, a segment characterized by intense competition and regulatory scrutiny. The global generic drug market is expected to continue growing, driven by increasing healthcare costs and the expiration of patents on branded drugs. Cosmos Health's focus on vertically integrated operations and its European distribution network positions it to potentially capitalize on these trends. However, it faces competition from larger, more established players with greater resources and market share. The company's ability to navigate regulatory landscapes and differentiate its product offerings will be critical for success.

Who Are COSM's Key Customers?

  • Wholesale pharmaceutical distributors
  • Independent retail pharmacies
  • Individual consumers through e-commerce
  • Healthcare providers
AI Confidence: 71% Updated: May 4, 2026

How COSM Is Valued

COSM carries a market capitalization of $17.00M, placing it in the micro-cap category. Relative to its peer group, COSM's quantitative score of 20/100 is below the peer average of 63/100.

ROE -96%Key Financial Metrics

Return on equity for COSM stands at -96.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -33.9%, showing how much profit it generates from its asset base. Its free cash flow yield is -96.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.08 indicates the company holds enough short-term assets to cover its near-term obligations.

F-Score 3/9Financial Health

COSM's Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -2.63 places it in the distress zone, a signal of elevated financial risk.

FY2026 estForward Outlook

Wall Street analysts project COSM revenue of about $87.3M for fiscal 2026, with EPS near $0.01.

COSM Financials

Fundamental Snapshot

Revenue Growth (FY)
+19.9%
Net Income Growth (FY)
-18.3%
EPS Growth (FY)
+46.2%
Free Cash Flow Growth (FY)
-4.5%
Return on Equity (TTM)
-96.5%
Current Ratio
1.1

Based on FMP financials and quantitative analysis · FY 2025

Bull Case vs Bear Case

Bull Case

  • Insider buying has increased recently, indicating confidence from those closest to the company.
  • Community sentiment has shifted positively, with discussions highlighting potential growth catalysts.
  • Recent product launches have garnered attention, suggesting a renewed interest in COSM's offerings.
  • Analysts are noting improvements in operational efficiency, which could enhance profitability moving forward.

Bear Case

  • Concerns over market competition have intensified, with peers launching similar products.
  • Social sentiment has shown some volatility, reflecting uncertainty among retail investors.
  • Recent earnings reports have raised questions about revenue sustainability, leading to cautious outlooks.
  • Investors are wary of macroeconomic factors that could impact overall market performance and consumer spending.

AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026

COSM Latest News

COSM Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for COSM.

Price Targets

Consensus target: $4.50

COSM MoonshotScore

20/100

What does this score mean?

The MoonshotScore rates COSM's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.

Leadership: Grigorios Siokas

CEO

Grigorios Siokas serves as the CEO of Cosmos Health Inc., overseeing the company's strategic direction and operational execution. His background includes extensive experience in the pharmaceutical and healthcare industries. He is responsible for managing the company's 149 employees and driving its growth initiatives. His expertise spans across product development, distribution, and commercialization within the healthcare sector.

Track Record: Under Grigorios Siokas's leadership, Cosmos Health has focused on expanding its proprietary product line and leveraging its European distribution network. Key milestones include the development of the company's e-commerce marketplace and the establishment of strategic partnerships with wholesale pharmaceutical distributors. He has been instrumental in navigating the company through a challenging financial landscape, focusing on improving profitability and operational efficiency.

COSM Healthcare Stock FAQ

What does Cosmos Health Inc. do?

Cosmos Health Inc. operates as a vertically integrated pharmaceutical company, focusing on the development, acquisition, and commercialization of a range of healthcare products. This includes branded and generic pharmaceuticals, nutraceuticals, over-the-counter medications, health care and baby products, and medical devices. The company distributes these products through its established distribution channels, including wholesale distributors, retail pharmacies, and its own e-commerce marketplace, primarily serving the European market.

What do analysts say about COSM stock?

Analyst ratings for Cosmos Health Inc. (COSM) are limited due to its small market capitalization and relatively short trading history. Key valuation metrics reflect the company's current financial challenges, including negative profitability and a low gross margin. Growth considerations center on the company's ability to successfully expand its proprietary product line, leverage its European distribution network, and improve operational efficiency. Investors should conduct thorough due diligence and consider the risks associated with investing in a micro-cap company.

What are the main risks for COSM?

The main risks for Cosmos Health Inc. include its small market capitalization, which makes it vulnerable to market volatility and liquidity issues. The company's negative profit margin and low gross margin indicate financial challenges that need to be addressed. Intense competition in the pharmaceutical industry, regulatory hurdles, and economic downturns also pose significant risks. Additionally, fluctuations in currency exchange rates can impact revenue and profitability in European markets, where Cosmos Health has a significant presence.

What are the key factors to evaluate for COSM?

COSM holds an AI score of 20/100 (low). P/E: 5.2x vs the S&P 500's ~20-25x. Analysts target $4.50 (+1544%). Not financial advice.

How frequently does COSM data refresh on this page?

COSM prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.

What has driven COSM's recent stock price performance?

COSM moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Vertically integrated operations. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider COSM overvalued or undervalued right now?

COSM trades at 5.2x earnings. Analysts target $4.50 (+1544%) — upside seen. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

What research should beginners do before buying COSM?

Before investing in COSM, research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources

Price as of Analysis updated AI Score refreshed daily
Data Sources & Methodology
Market data powered by Financial Modeling Prep & Yahoo Finance. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.
Data provided as-is for educational purposes. Not financial advice. Methodology

Data provided for informational purposes only.

Analysis Notes
  • Financial data is based on the most recent available information.
  • Analyst opinions may vary and should not be considered as investment advice.
  • This dossier is for informational purposes only and does not constitute a recommendation to buy or sell securities.
Data Sources

Popular Stocks